Digest Network How does it work
Network
/
Society
Al
Not verified

Alnylam Pharmaceuticals, Inc.

What we write about

BiotechnologyHealthMedicine - variousPharmaceuticalsWEB AND SOCIAL NETWORK

56 Press releases

View all press releases
17/12/2025
Industria
Biotechnology
Food hygiene
Health
Pharmaceuticals
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
11/12/2025
Stocks and shares
Biotechnology
Pharmaceuticals
Health
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
03/12/2025
Labour market
Biotechnology
Pharmaceuticals
Health
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
08/11/2025
Scienza
Cardiology
Biotechnology
Pharmaceuticals
Health
Food hygiene
Medicine - various
Eventi
Market analysis
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
04/11/2025
WEB AND SOCIAL NETWORK
Eventi
Finance
Biotechnology
Pharmaceuticals
Health
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
30/10/2025
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Biotechnology
Health
Pharmaceuticals
Medicine - various
Cardiology
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
16/10/2025
Biotechnology
Pharmaceuticals
Health
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
Finance
stock market
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
01/10/2025
Biotechnology
Pharmaceuticals
Health
Cardiology
Industria
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
29/09/2025
Biotechnology
Pharmaceuticals
Health
Cardiology
Eventi
Industria
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0
28/09/2025
Biotechnology
Pharmaceuticals
Health
Cardiology
Eventi
Industria
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Source
Alnylam Pharmaceuticals, Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0